Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer
- 8 March 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 588, 216780
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education
- National Science and Technology Council (112-2639-B-039-001 \u2013 ASP)
- National Science and Technology Council (111-2314-B-039-007)
- Ministry of Education
- Ministry of Education - Singapore
- China Medical University
- Ministry of Health and Welfare (MOHW112-TDU-B-222-124016)
This publication has 163 references indexed in Scilit:
- Molecular characterization ofMETfusions from a large real‐world Chinese population: A multicenter studyCancer Medicine, 2023
- Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cellsCellular and Molecular Life Sciences, 2022
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsThe Oncologist, 2021
- A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastasesBreast Cancer Research and Treatment, 2019
- Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancerBreast Cancer Research and Treatment, 2016
- MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2Journal of Cancer Research and Clinical Oncology, 2015
- C‐Met in invasive breast cancerCancer, 2013
- Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerCancer, 2012
- Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10Clinical & Experimental Metastasis, 2011
- Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.The EMBO Journal, 1992